Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. Using cell‐based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Cancer
Egile Nagusiak: Sugawara, Tatsuo, Baumgart, Simon J., Nevedomskaya, Ekaterina, Reichert, Kristin, Steuber, Holger, Lejeune, Pascale, Mumberg, Dominik, Haendler, Bernard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2019
Gaiak:
Molecular Cancer Biology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766977/
https://ncbi.nlm.nih.gov/pubmed/30828788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32242
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak